Essentials of Antimicrobial Stewardship

Apurba S Sastry MD (JIPMER) DNB MNAMS PDCRKetan Priyadarshi MD (IMS-BHU) DNB PDCC-Infectious Diseases PDF-Hospital Infection Control (JIPMER)Deepashree R MD (Gold Medal) DNB MNAMS

• Section 1: Core Components of Antimicrobial Stewardship1. Introduction to Antimicrobial Stewardship2. Implementation of Antimicrobial Stewardship Program2.1. Core Elements of AMS Program2.2. Steps of Implementation of AMS Program in a Hospital2.3. Role of Information Technology in AMS Program2.4. AMS Interventions2.5. Role of Behavioral Change in AMS3. Monitoring of Antimicrobial Stewardship4. Current Scenario of Antimicrobial Resistance and Role of AMR Surveillance Section 2: Diagnostic Stewardship5. Introduction to Diagnostic Stewardship6. Role of Appropriate Specimen Collection7. Role of Direct Microscopy8. Accurate Processing of Clinical Specimens and Reporting of Cultures9. Role of Accurate Microbial Identification10. Basics of Antimicrobial Susceptibility Testing11. Interpretation of Antimicrobial Susceptibility Testing12. Detection of Specific Antimicrobial Resistance13. Quality Control in Antimicrobial Susceptibility Testing14. Direct Susceptibility Testing15. Selective Reporting and Role of Breakpoint-to-MIC Quotient16. Comments in Clinical Microbiology Reporting17. Role of Biomarkers and Point-of-care Tests (POCT) in AMS Section 3: Hospital Antibiogram18. Introduction to Antibiogram19. Routine Antibiogram20. Specialized Antibiograms21. Use of Antibiogram22. Analysis of MDR/XDR/PDR Phenotypes Section 4: Antimicrobial Agents23. Antimicrobial Agents: Classification and PK-PD Considerations24. Cell Wall Active Agents-I: B-lactams25. Cell Wall Active Agents-II: Glycopeptides and Fosfomycins26. Cell Membrane Acting Agents: Polymyxins and Daptomycin27. Protein Synthesis Inhibitors: Aminoglycosides, Tetracyclines, Glycylcyclines, Macrolides, Lincosamides, Oxazolidinones, Streptogramins, Chloramphenicol and Others28. Nucleic Acid, Folic Acid Synthesis Inhibitors and Others: Quinolones, Nitroimidazoles, Nitrofurans,Cotrimoxazole and Topical Agents29. Antitubercular Drugs and Treatment Guidelines30. Antiviral Drugs31. Antifungal Drugs32. Antiparasitic Drugs Section 5: Antimicrobial Therapy (Clinical Stewardship)33. Empirical Antimicrobial Therapy33.1. Cardiovascular Infections33.2. Sepsis and Bloodstream Infections33.3. Central Nervous System Infections33.4. Intra-abdominal Infections33.5. Skin and Soft Tissue Infections33.6. Respiratory Tract Infections33.7. Genito-urinary Tract Infections33.8. Bone and Joint Infections33.9. Post-cardiovascular Surgery Infections33.10. Ocular Infections33.11. Ear Infections33.12. Burn Wound Infections33.13. Antimicrobial Policy in Febrile Neutropenia33.14. Infections in Solid Organ Transplant Recipients (Non-neutropenic Settings)33.15. Pediatric Infections33.16. Neonatal Infections34. Targeted Antimicrobial Therapy for Gram-positive Bacterial Infections35. Targeted Antimicrobial Therapy for Gram-negative Bacterial Infections36. Antifungal Stewardship and Treatment of Fungal Infections37. Antimicrobial Prophylaxis Section 6: Miscellaneous38. Antimicrobial Stewardship in Special Situations38.1. AMS in Outpatient Setting38.2. AMS in Outpatient Parenteral Antimicrobial Therapy (OPAT) Settings38.3. AMS in Long-term Care Facility Setting38.4. AMS in Critical Care Units38.5. AMS in Immunocompromised Patients38.6. AMS in Pediatric Units38.7. AMS in Community Hospitals39. One Health Approach in Antimicrobial Stewardship40. Hospital Source Control–Unmet Need of an Integrated Antimicrobial Stewardship Practice41. Puzzles in Rational Use of Antimicrobial Agents